A new study describes the structure of a crucial enzyme present in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for coronavirus disease 2019 ...
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
a) ≥2 consecutive MRI scans with negative finding. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
Just a few short months after Johnson & Johnson's Janssen unit sent its targeted non-small cell lung cancer (NSCLC) drug amivantamab to the FDA, the regulator has come back with a green light—a very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results